Efficacy and safety of sunitinib alternate day regimen in patients with metastatic renal cell carcinoma in Japan: Comparison with standard 4/2 schedule

ConclusionSunitinib administered q.a.d. was safe and effective for mRCC patients. We speculate that the persistent optimal drug plasma concentrations contributed to these effects.

Source: Asia-Pacific Journal of Clinical Oncology - January 31, 2018 Category: Cancer & Oncology Authors: Kojiro Ohba, Yasuyoshi Miyata, Takuji Yasuda, Akihiro Asai, Kensuke Mitsunari, Tomohiro Matsuo, Yasushi Mochizuki, Noriko Matsunaga, Hideki Sakai Tags: ORIGINAL ARTICLE Source Type: research